Methoxsalene G.L. Pharma (Methoxsalen)

Methoxsalen intercalates into DNA and, when activated by UVA light, creates covalent cross‑links that block DNA replication. This photochemical action suppresses abnormal skin cell proliferation and modulates local immune responses, providing therapeutic effects in the targeted skin conditions.

The dosing regimen for methoxsalen is individualized by the prescribing clinician based on the specific indication, patient characteristics and the planned UVA exposure. Healthcare providers determine the appropriate amount and schedule for each patient.

Safety data for methoxsalen in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the possible risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare professional.

To request Methoxsalene G.L. Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methoxsalen is the most widely used psoralen for PUVA therapy, offering a well‑characterized safety and efficacy profile. Compared with alternative psoralens, it has similar photochemical activity but may differ slightly in pharmacokinetics, allowing clinicians to select the agent best suited to the patient’s treatment plan.

Methoxsalene G.L. Pharma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain stability and potency.

Methoxsalene G.L. Pharma is applied extracorporeally; the solution is administered systemically or topically before a controlled UVA exposure session (PUVA). The exact method and timing are determined by the treating physician according to the therapeutic protocol.

Serious risks include phototoxic burns, increased long‑term risk of skin cancers, severe allergic reactions and hemolysis in patients with G6PD deficiency. Patients should be monitored closely for early signs of these events, and therapy should be discontinued if severe reactions occur.

Methoxsalene G.L. Pharma is contraindicated in individuals with porphyria, known hypersensitivity to psoralens, active skin infections, or those taking certain photosensitizing medications. Pregnant or breastfeeding women should only use it if clearly indicated by a healthcare professional.